Results Each propensity-score matched group constituted 3424 patients, 45% women, 21% had a history of cardiovascular disease, and 13.9% were treated with sodium-glucose cotransporter-2 inhibitors at baseline
The objective of this review is to summarize the main renal outcomes from clinical studies while providing practical guidance on the use of GLP-1 RAs
Liraglutide improved learning and memory performance, attenuated hyperphosphorylation of tau as well as NFs, and prevented neurodegeneration via improving JNK and ERK signaling in brain of 3Tg mice (232)
Taken together, our findings suggest that the albuminuria-lowering effects of GLP-1 RAs observed in RCTs are also relevant in a general population of patients with type 2 diabetes with a lower cardiovascular and kidney risk profile
To view or add a comment, sign in More Relevant Posts Editor's Choice: This review highlights the latest evidence-based approaches to #obesity management, spanning behavioral, nutritional, pharmacologic, and surgical interventions
